The use of IL-1 and IL-6 receptor antagonists such as tociluzimab has been seen to reduce the severity of acute COVID-19 illness in patients, which in turn may reduce the neurological damage that occurs secondary to the cytokine storm (Ghofrani Nezhad et al., 2023). This evidence concerns the gene IL1B and COVID-19.